Next, we used the programmable knockdown capacity of the Cas13a machinery to target ALK RNA in EML4-ALK fusion transcripts in H3122 lung cancer cells, with the goal of decreasing cell viability and providing proof-of-principle of a novel therapeutic approach. This evidence concerns the gene EML4 and lung carcinoma.